Predictors of end stage renal disease in African Americans with lupus nephritis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 68, Issue 4, 2010, Pages 251-256

  Franco, Carlos ^a   Yoo, Wonsuk ^c   Franco, Domingo ^d   Xu, Zeng ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b Department of Pathology ^*  (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSIDAD CATÓLICA NUESTRA SEÑORA DE LA ASUNCIÓN   (Paraguay)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID;

ADULT; ADVERSE OUTCOME; AFRICAN AMERICAN; ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DIALYSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 78651230404     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002 Apr;46(4):995-1002.
2. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006 May;69(10):1846-1851.
3. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994 Feb;45(2):544-550.
4. Dooley MA. Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH (eds): Dubois Lupus Erythematosus. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2007, pp. 1112-1130.
5. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. Am Soc Nephrol. 2007 Jan;18(1):244-254.
6. Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000 May;35(5):9,4,14.
7. Adler M, Chambers S, Edwards C, et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25 year period. Rheumatology. 2006 Sept;45(9):1144-1147.
8. Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore). 1977 Nov;56(6):527-536.
9. Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol. 1996 Feb;7(2):299-305.
10. Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int. 1987 Aug;32(2):274-279.
11. Alarcon GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII (correction of VIII). Predictors of early mortality in the LUMINAL cohort. LUMINA Study group. Arthritis Rheum. 2001 Apr;45(2):191-202.
12. Yang Y, Hebert LA, Chung EK, et al. Caucasian patients with systemic lupus erythematosus (SLE) nephritis have low C4A gene copy numbers and low plasma C4 protein levels. Molecular Immunology [Abstract]. 2007 Jan;44(1-3):261.
13. Moroni G, Radice A, Giammarresi G, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6 year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009 Feb;68(2):234-237.